Norway's regulatory framework for health products is overseen by the Norwegian Medicines Agency (Statens legemiddelverk, NOMA) for pharmaceuticals and certain diagnostics, while medical devices and in vitro diagnostics fall under the Norwegian Board of Health Supervision (Statens helsetilsyn) and are governed by EU regulations through Norway's membership in the European Economic Area (EEA). As an EEA member state, Norway adopts EU health product legislation, including the EU Medical Device Regulation (MDR 2017/745), the In Vitro Diagnostic Regulation (IVDR 2017/746), and the centralised and decentralised pharmaceutical approval procedures administered through the European Medicines Agency (EMA). Pharmaceuticals approved via the EMA centralised procedure are automatically valid in Norway, while national and mutual recognition procedures are managed through NOMA. Digital health solutions are increasingly regulated under the Medical Device framework where software qualifies as a medical device, and the Norwegian Directorate of eHealth (Direktoratet for e-helse) plays a coordinating role in digital health governance.
Market authorisation applications for pharmaceuticals must follow the Common Technical Document (CTD) format, consistent with ICH guidelines, and Norway participates fully in EU-wide submission and assessment procedures. A local representative (Norwegian or EEA-based) is required for all marketing authorisation holders not established within the EEA. Medical devices must bear CE marking issued by a recognised Notified Body before being placed on the Norwegian market. NOMA has implemented reforms aligned with the EU pharmaceutical strategy, including accelerated assessment pathways for medicines addressing unmet medical needs and enhanced post-market surveillance requirements. Norway also participates in the HTA cooperation framework under Regulation (EU) 2021/2282, which is shaping joint clinical assessments across EEA countries, increasingly influencing national reimbursement and access decisions.
Public procurement of health products in Norway is centralised through several key bodies operating under the Ministry of Health and Care Services (Helse- og omsorgsdepartementet). The four regional health authorities, Helse Nord, Helse Midt-Norge, Helse Vest, and HelseSor-Ost, are responsible for hospital-based procurement and collectively coordinate through SYKEHUSINNKJOP HF, the national hospital procurement organisation established to consolidate tendering and achieve cost efficiencies. National pharmaceutical tenders for hospital medicines are coordinated through SYKEHUSINNKJOP HF, while the Norwegian Medicines Agency administers the reimbursement system (blaareseptordningen) for outpatient prescription medicines, evaluating cost-effectiveness and budget impact as prerequisites for public funding. Procurement must comply with the Norwegian Public Procurement Act (Lov om offentlige anskaffelser) and aligns with EEA procurement directives, requiring open tender procedures above defined thresholds. Health Technology Assessment (HTA) conducted by the Norwegian Institute of Public Health (Folkehelseinstituttet, FHI) on behalf of the national system informs reimbursement and formulary decisions for both pharmaceuticals and medical technologies.
Norway is a high-income country and does not rely on donor-funded procurement channels such as UNICEF Supply Division, the Global Fund, USAID, or Gavi for domestic health product supply. The private healthcare market exists but remains relatively limited given the strength of the publicly funded system. Local manufacturing preference policies are not a prominent feature of Norwegian procurement, which prioritises value-for-money, quality, and compliance with EEA standards. However, Norway contributes significantly to global health financing and participates in international procurement initiatives through its foreign development aid programmes, particularly for low- and middle-income countries, channelled through organisations such as the Norwegian Agency for Development Cooperation (Norad) and multilateral health bodies.
This is a generic market overview. For a structured entry brief tailored to your product category, including regulatory pathway, pricing, and risk assessment, use the Market Brief tool.
Generate a free Market Brief for Norway →